"WASHINGTON, DC â€” In addition to significantly lowering levels of LDL-C, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (Repatha, Amgen) decreased major CV-events risk, according to results from the long-an"...
VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/2/2017
Additional Vascepa Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Tips to keep it under control.